Novorapid Flextouch (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Flextouch, is a rapid‑acting insulin analog presented as a solution for injection for subcutaneous use. It treats diabetes mellitus type 1 and type 2 by providing fast post‑prandial glucose control.

GNH USA supplies Novorapid Flextouch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novorapid Flextouch, a rapid‑acting insulin analog, is used to manage blood glucose in diabetes and related hyperglycemic conditions.

- Diabetes mellitus type 1: provides rapid post‑meal insulin to match carbohydrate intake and reduce hyperglycemia. - Diabetes mellitus type 2: added to oral agents or basal insulin for intensive glycemic control when meals cause spikes. - Hospital‑related hyperglycemia: used for quick correction of elevated blood glucose in inpatient settings.

The most frequently reported reactions to rapid‑acting insulin analogues involve glucose regulation and injection site responses.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are delayed or doses are excessive. - Injection site pain or erythema: mild discomfort or redness at the injection site. - Weight gain: modest increase associated with improved glycemic control. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare systemic allergic response with rash, swelling, or respiratory difficulty. - Hypokalemia: low potassium levels secondary to insulin‑driven cellular uptake. - Insulin edema: fluid retention causing peripheral swelling.

When using Novorapid Flextouch, several precautions should be observed to ensure safety and effectiveness. - Hypoglycemia risk: monitor blood glucose before meals and adjust dose as needed. - Renal impairment: use cautiously and consider dose reduction in patients with reduced kidney function. - Pregnancy considerations: only use if the potential benefit outweighs potential risk to the fetus. - Alcohol consumption: may potentiate insulin‑induced hypoglycemia; advise patients to limit intake. - Concomitant beta‑blockers: can mask hypoglycemia symptoms, requiring closer glucose monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin aspart may interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid): - Beta‑blockers: can conceal hypoglycemia symptoms, making detection difficult. - MAO inhibitors: may potentiate insulin’s hypoglycemic action. - Concurrent use of other insulin products: increases risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Sulfonylureas or other oral hypoglycemics: additive glucose‑lowering effect raises hypoglycemia risk. - Thiazide diuretics: may elevate blood glucose, requiring insulin dose adjustment. - Corticosteroids: can increase insulin resistance, necessitating higher doses. - Alcohol: can cause delayed hypoglycemia, especially with missed meals.